EILEEN JUSTO: Open Payments
NPI 1689230500 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,266 in 283 payments from 33 companies in 2025. Trend: 2023 $4,674 · 2024 $4,466 · 2025 $5,266
Food & beverage: $5,266
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 65 | $1,048 |
| Novartis Pharmaceuticals Corporation | 40 | $414 |
| ACADIA Pharmaceuticals Inc | 20 | $382 |
| UCB, Inc. | 17 | $350 |
| SK Life Science, Inc. | 8 | $331 |
| PFIZER INC. | 19 | $320 |
| Biogen, Inc. | 11 | $294 |
| Otsuka America Pharmaceutical, Inc. | 12 | $233 |
| Genentech USA, Inc. | 9 | $208 |
| Celgene Corporation | 14 | $177 |
Products named: QULIPTA, KESIMPTA, NUPLAZID, UBRELVY, NURTEC ODT, REXULTI, Ocrevus Zunovo, ZEPOSIA.
Industry payments across NV — which companies pay providers there.
